17,515 Shares in Silence Therapeutics plc (NASDAQ:SLN) Purchased by FNY Investment Advisers LLC

FNY Investment Advisers LLC acquired a new position in shares of Silence Therapeutics plc (NASDAQ:SLN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 17,515 shares of the company’s stock, valued at approximately $120,000. FNY Investment Advisers LLC owned approximately 0.06% of Silence Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of SLN. Eventide Asset Management LLC bought a new position in shares of Silence Therapeutics during the third quarter valued at $11,635,000. Millennium Management LLC increased its stake in Silence Therapeutics by 91.2% during the 2nd quarter. Millennium Management LLC now owns 782,941 shares of the company’s stock valued at $14,876,000 after purchasing an additional 373,523 shares in the last quarter. Point72 Asset Management L.P. increased its stake in Silence Therapeutics by 219.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock valued at $8,505,000 after purchasing an additional 321,300 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Silence Therapeutics by 32.8% in the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock worth $19,798,000 after buying an additional 268,250 shares during the last quarter. Finally, Parkman Healthcare Partners LLC lifted its stake in shares of Silence Therapeutics by 71.8% in the third quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock worth $9,051,000 after buying an additional 208,029 shares in the last quarter. Institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Stock Performance

Shares of Silence Therapeutics stock opened at $5.61 on Wednesday. The stock has a market cap of $167.90 million, a P/E ratio of -3.57 and a beta of 1.08. The stock’s fifty day moving average is $8.59 and its 200 day moving average is $15.03. Silence Therapeutics plc has a one year low of $5.58 and a one year high of $27.72.

Analyst Upgrades and Downgrades

SLN has been the subject of several research analyst reports. Chardan Capital reiterated a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a report on Tuesday, December 10th. William Blair restated an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a report on Monday, December 9th. Morgan Stanley reissued an “overweight” rating and issued a $49.00 target price on shares of Silence Therapeutics in a research report on Tuesday, October 8th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Silence Therapeutics presently has an average rating of “Buy” and a consensus price target of $57.20.

Silence Therapeutics Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.